DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the PE ratio of Shree Ganesh Remedies Ltd?

Shree Ganesh Remedies Ltd has a price-to-earnings (PE) ratio of 49.0 in the Healthcare sector.

What is the market capitalisation of Shree Ganesh Remedies Ltd?

Shree Ganesh Remedies Ltd has a market capitalisation of approximately ₹860 crore.

Shree Ganesh Remedies Ltd

SHREEGANESHREMEDIESLTD·NSE·Healthcare

₹0.00▲ +0.00 (+0.00%)

⚠️Trading suspended. Not a live price.

Healthcare · Pharmaceuticals

A steady, established business

52W₹381

₹759-101%

Open

—

High

—

Low

—

Prev Close

—

Volume

—

VWAP

—

Snapshot

Key fundamentals

Market Cap

₹860 Cr

P/E Ratio

49.00Expensive

P/B Ratio

5.34

EPS

₹18.00

Book Value

₹126.95

ROE

11.50%Average

ROCE

19.00%Efficient

Dividend Yield

0.07%

Debt / Equity

0.19Low

Face Value

₹10.00

52W High

₹759.00

52W Low

₹381.10

Sector

Healthcare

Industry

Pharmaceuticals

Fairly Valued

Narrow moatHigh uncertainty

Fair value estimate

₹175

No recent traded price

BearFair valueBull

₹149₹175₹250

/100

Business quality — Solid

Growth 50Profitability 66Efficiency 55Valuation 47

Plain English

Our view

A steady, established business
Low debt relative to equity

Strengths

Low debt relative to equity
Promoters hold a controlling stake

How we got there

Fair value methods

Residual income

16% ROE fading to 12% over ~10 yrs, on ₹127 book

₹154

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹250

Analyst target

No analyst coverage

—

Blended fair value₹175

What the numbers say

Investment thesis

Bull case

Low debt relative to equity
Promoters hold a controlling stake

Bear case

No notable red flags from the current metrics.

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

49.0Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

11.5%Average

Above 15% is considered healthy for Indian equities

ROCE

19.0%Efficient

Above 18% means capital is working hard

Debt/Eq

0.19Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹860 Cr

P/B

5.34

EPS

₹18.00

Div Yield

0.07%

What changed

Recent changes

No notable changes to report.

What matters

News impact

Overview

Valuation

Expensive

P/E 49.0×

Growth

Steady

+6% rev CAGR

Profitability

Modest

11.5% ROE

Financial health

Rock solid

D/E 0.19

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover—

Trades—

VWAP—

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+6.3%

+17.4%

10Y

+21.2%

Profit

+6.8%

+12.8%

10Y

+33.7%

EPS

+22.7%

+23.5%

10Y

+12.5%

Profile

Pros

Company's median sales growth is 29.5% of last 10 years

Watch-outs

Cons

Though the company is reporting repeated profits, it is not paying out dividend
Debtor days have increased from 80.8 to 109 days.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Ownership was broadly stable versus the previous quarter. The QoQ column shows each group's change versus the prior quarter.

73%

Promoter

Promoters

72.8%+0.04

Public

25.0%+0.02

FII / FPI

0.0%0.00

DII

0.0%0.00

Others

2.2%

Total shareholders

8,058-384 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter72.84%

Public24.97%

Others2.19%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1995, Shree Ganesh Remedies Ltd is a manufacturer of Pharmaceutical Drug Intermediates for API & Fine Chemicals[1]